PROCESS Trial: Effect of Duloxetine Premedication for Postherpetic Neuralgia Within 72 Hours of Herpes Zoster Reactivation—A Randomized Controlled Trial
Clinical Infectious Diseases · 10.04.2024 · 78 (4) · 880-888
DOI: 10.1093/cid/ciad714 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 28.11.2023. Verfasst von Chunmei Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Neuralgia, Postherpetic, Herpes Zoster. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Capital's Funds for Health Improvement and Research, Capital Medical University Research and Cultivation.
Abstract (Originalsprache)
Background
Postherpetic neuralgia (PHN) is the most common chronic complication of herpes zoster (HZ) and results in severe refractory neuropathic pain. This study aimed at evaluating the efficacy of premedication with duloxetine in the prevention of PHN.
Methods
The PROCESS trial is a multicenter, randomized, open-label, blinded-endpoint trial used a 1:1 duloxetine:control ratio. Adults 50 years or older with HZ who presented with vesicles within 72 hours were recruited. The primary outcome was the incidence of PHN at 12 weeks. PHN was defined as any pain intensity score other than 0 mm on the visual analog scale (VAS) at week 12 after the onset of the rash. The secondary outcomes were the number of participants with VAS >0 and VAS ≥3. The modified intention-to-treat (mITT) principle and per-protocol (PP) principle were used for the primary outcome analysis.
Results
A total of 375 participants were randomly assigned to the duloxetine group and 375 were assigned to the control group. There was no significant difference in the incidence of PHN in the duloxetine group compared with the control group in the mITT analysis (86 [22.9%] of 375 vs 108 [28.8%] of 375; P = .067). PP analysis produced similar results. However, there were significant differences between the 2 groups in the number of participants with VAS >0 and VAS ≥3 (P < .05 for all comparisons).
Conclusions
Although absolute prevention of PHN does not occur, this trial found that premedication with duloxetine can reduce pain associated with HZ, and therefore can have clinically relevant benefits. Clinical Trials Registration. Clinicaltrials.gov, NCT04313335. Registered on 18 March 2020.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Pain Management, Peking University People's Hospital, Beijing, China.
- Department of Pain Management, China-Japan Friendships Hospital, Beijing, China.
- Emergency Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Fang Luo
Förderung
- Capital's Funds for Health Improvement and Research
- Capital Medical University Research and Cultivation
Zitieren
APA
Zhao, C., Zhang, T., Zhu, Q., Chen, Z., Ren, H., Shrestha, N., Meng, L., Shen, Y., & Luo, F. (2024). PROCESS Trial: Effect of Duloxetine Premedication for Postherpetic Neuralgia Within 72 Hours of Herpes Zoster Reactivation—A Randomized Controlled Trial. Clinical Infectious Diseases, 78(4), 880-888. https://doi.org/10.1093/cid/ciad714
Vancouver
Zhao C, Zhang T, Zhu Q, Chen Z, Ren H, Shrestha N, et al. PROCESS Trial: Effect of Duloxetine Premedication for Postherpetic Neuralgia Within 72 Hours of Herpes Zoster Reactivation—A Randomized Controlled Trial. Clinical Infectious Diseases. 2024;78(4):880-888. doi:10.1093/cid/ciad714
BibTeX
@article{Zhao2024,
author = {Zhao, Chunmei and Zhang, Tingjie and Zhu, Qian and Chen, Zheng and Ren, Hao and Shrestha, Niti and Meng, Lan and Shen, Ying and Luo, Fang},
title = {PROCESS Trial: Effect of Duloxetine Premedication for Postherpetic Neuralgia Within 72 Hours of Herpes Zoster Reactivation—A Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {4},
pages = {880--888},
doi = {10.1093/cid/ciad714}
}
EUVIMED